Not yet taking people in ItalyPhase 1
Tests immunotherapy combinations before surgery for high-risk melanoma
Tests immune-boosting drugs given before surgery in adults with melanoma skin cancer.
Key facts
- Who runs it
- Fondazione Melanoma Onlus
- Where
- Meldola, Milan, Naples, Padova, Perugia, and Rome, ItalySee the 8 sites
- Trial code
- Registry title
- A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 80 people, planned
- Started
- 2 Sept 2025
- Expected to end
- 2 Sept 2031
- Type of study
- Interventional
- Record updated
- 27 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high-risk melanoma that can be removed by surgery. It tests medicines given before surgery.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- High-risk melanoma that can be removed by surgery.
Where in Italy
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.lMeldola, ItalyNot yet recruiting
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyNot yet recruiting
- Istituto Europeo di Oncologia s.r.lMilan, ItalyNot yet recruiting
- Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi VanvitelliNaples, ItalyNot yet recruiting
- IRCCS Istituto Nazionale Tumori Fondazione PascaleNaples, ItalyNot yet recruiting
- Istituto Oncologico VenetoPadova, ItalyNot yet recruiting
- Hospital Santa Maria Della MisericordiaPerugia, ItalyNot yet recruiting
- I.F.O. Istituti Fisioterapici OspitalieriRome, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests immunotherapy combinations before surgery for high-risk melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 October 2026